Current genetic biomarkers fail to predict responders to hypomethylating agents (HMAs) in myeloid cancers. Here, the authors employ a variety of single cell epigenomic assays to identify the epigenomic state of the leukemic stem cell, prior to therapy, as the determinant of HMA-responsiveness in myeloid malignancies.
- Aparna Gopal
- Derek Tam
- Aly Karsan
